The takeaway
UroGen Pharma Ltd shows a pronounced seasonal pattern over 9 years of data — strongest in June (+27.6%) and softest in July (+13.5%).
Right now
In July, the stock has risen 22% of years, averaging +13.5%, about +11.4 pts better than the S&P 500.
The full picture
UroGen Pharma Ltd's most dependable month has been June, higher in 6 of 9 years; July has been its least reliable, up just 22% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in June (+27.4 pts); it has trailed the market most in May (−11.9 pts).
“vs S&P” is UroGen Pharma Ltd’s average for a month minus the S&P 500’s average for that same month — isolating UroGen Pharma Ltd’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, June has closed higher 80% of the time versus 67% across the last 9 years — the pattern is strengthening.
Figures are the typical (median) June return and how often it rose — the last 5 years versus the last 9(the heatmap’s default window). This verdict stays anchored to that 9-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
This is a feast-or-famine calendar. June reads as the strong month, higher in 6 of 9 Junes, but the tale is one of a few outsized years more than steady gains.
Read it with one caveat: the average (+27.6%) runs well ahead of the median (+5.9%), so a handful of outsized years — not steady strength — do much of the lifting. That reliability comes with real swings, mind — even June ranges by 59.2% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — June has outpaced the S&P 500 by +27.4 points on average. Few peers keep such company in June — the typical stock clears it just 52% of the time.
It doesn't stand entirely alone — January, August, and November have leaned firm as well, if less emphatically. On the other side of the ledger, July is the year's low point, though even there the stock has stayed positive on average (+13.5%), a sign every month leans up, and the edge isn't year-round — the stock has trailed the S&P 500 in May, December, and February. Its roughest month on record was a −62.8% May in 2025 — a reminder of how hard even a seasonal name can fall.
If anything it has sharpened recently — the last five Junes run ahead of the earlier years.
Hold it loosely, then: the June tendency is genuine but lumpy, more about the occasional outsized year than a gain to bank on. With a short 9-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (June), its worst (July), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2017 its best month (June, +27.6%) has run well ahead of its worst (July, +13.5%) — the heatmap above shows how steady that gap has been year to year.
June has been the strongest, averaging +27.6% and closing higher in 6 of 9 years since 2017.
It's the weakest month, but it has still averaged a small gain (+13.5%) — quiet rather than genuinely bad.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade